Discovery Plans Complete Response on Surfaxin in September

Drug Industry Daily
A A
Discovery Laboratories is planning to submit its complete response to the FDA’s third Surfaxin approvable letter in September. The synthetic surfactant-replacement therapy is awaiting approval for the prevention of respiratory distress syndrome (RDS) in premature infants.

To View This Article:

Login

Subscribe To Drug Industry Daily